Agilent Technologies and Ameritox Form Collaboration, Aim to Advance Analysis of Medication Monitori

Before you go, we thought you'd like these...
Before you go close icon

Agilent Technologies and Ameritox Form Collaboration, Aim to Advance Analysis of Medication Monitoring

SANTA CLARA, Calif. & BALTIMORE--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYS: A) and AmeritoxSM today announced that they have formed a research collaboration that could accelerate analysis in the field of medication monitoring.

"By using multiple RapidFire systems Ameritox is streamlining the analysis of small panels of exogenous compounds compared to traditional methods of analysis," said Can Ozbal, director of Agilent's RapidFire business.


While Agilent's RapidFire system has been used extensively in pharmaceutical and biopharmaceutical laboratories, this research collaboration with Ameritox is one of the first for Agilent's RapidFire team in the field of medication monitoring.

"By working together and sharing moment-by-moment laboratory activity, this research arrangement gives both Ameritox and Agilent a vantage point from which we can continue to discover new uses for our science and technology," said Jay Zimmerman, chief laboratory officer of Ameritox.

"The marriage of Agilent's technology and Ameritox's proprietary science could hold the key to major advancements in the field of medication monitoring," Zimmerman said.

About Ameritox

Ameritox is the nation's leader in Pain Medication Monitoring SolutionsSM, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process - Rx GuardianSM - with Rx Guardian CDSM, the only pain medication monitoring process with a proprietary normalization algorithm and a reference database of pain patients clinically assessed for adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Monitoring through prescription drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at www.ameritox.com, on Twitter @Ameritox, on Facebook at facebook.com/ameritox, and on YouTube at www.youtube.com/ameritox.

About Agilent Technologies

Agilent Technologies Inc. (NYS: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.



Agilent
Susan Berg, +1-408-553-7093
susan_berg1@agilent.com
or
Ameritox
Lon Wagner, +1-336-387-7742
Lon.Wagner@ameritox.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:

The article Agilent Technologies and Ameritox Form Collaboration, Aim to Advance Analysis of Medication Monitoring originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners